Healthcare Firms Detail Growth Plans, Natera Names CEO

At the Stifel healthcare conference, Boston Scientific said its Interventional Therapies division generates about $5 billion in annual revenue and could grow to roughly 35% of company sales after the Penumbra acquisition, while projecting sustained high-single-digit to double-digit growth despite near-term product and supply challenges. The company expects to compete through clinical and technological differentiation, while working to address pressure in areas including TCAR, pulsed-field ablation and WATCHMAN. At the Wolfe Research conference, Mobia Medical highlighted clinical-trial results, new guideline support and improved reimbursement for its Vivistim stroke-recovery device, but said broader adoption will depend on provider and patient education, payer confidence and real-world evidence. Natera announced an immediate CEO transition to Solomon Moshtaghian and reaffirmed an ambitious goal of $6 billion in revenue by 2029, with its Signatera cancer test as the central growth driver. Natera sees reimbursement gains, higher average selling prices, expanding clinical evidence and wider adoption as important to that plan, while acknowledging intensifying competition and pricing pressures.